Physician profile
Heather Scott Pulaski
NPI 1033230354
$74,749.74
in general payments reported to CMS, 2019-2025
38 companies · $25K in 2025
The $25K reported for 2025 was more than what 95% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2021: $9,484 · 2022: $707 · 2023: $14K · 2024: $25K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Travel and Lodging: $8,568 · Food and Beverage: $4,443 · Consulting Fee: $1,388 · Education: $19.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,000.00 |
| Travel and Lodging | $8,568.00 |
| Food and Beverage | $4,443.17 |
| Consulting Fee | $1,387.50 |
| Education | $19.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $60,449.26 | 2021-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals Lp | $11,441.48 | 2021-2025 | Lynparza, Imjudo, Imfinzi |
| Tempus Ai, INC | $497.48 | 2025 | Xt Cdx |
| Myriad Genetic Laboratories, INC. | $323.45 | 2022-2024 | Myrisk |
| Intuitive Surgical, INC. | $227.97 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $201.90 | 2023-2025 | Libtayo, Lynozyfic |
| Genmab U.S., INC. | $159.34 | 2022-2025 | Tivdak |
| Astellas Pharma US INC | $142.60 | 2024-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $134.42 | 2023 | Pomalyst |
| Merck Sharp & Dohme LLC | $131.37 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Coopersurgical, INC. | $111.50 | 2019 | |
| Janssen Biotech, INC. | $104.13 | 2022-2024 | Darzalex, Tecvayli |
| Incyte Corporation | $65.19 | 2023-2024 | Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $57.93 | 2025 | Iclusig, Ninlaro |
| Integra Lifesciences Corporation | $53.55 | 2023-2024 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Certas |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Pulaski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.